Role of the serotonin transporter in pulmonary arterial hypertension

References

• Kramer MS, Lane DA. Aminorex, dexfenfluramine, and primary pulmonary hypertension. J. Clin. Epidemiol.51(4), 361–364 (1998).
   PubMedGoogle Scholar
• Abenhaim L, Moride Y, Brenot F et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N. Engl. J. Med.335(9), 609–616 (1996).
   PubMed Web of Science ®Google Scholar
• Rothman RB, Ayestas MA, Dersch CM, Baumann MH. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates: implications for primary pulmonary hypertension. Circulation100(8), 869–875 (1999).
   PubMedGoogle Scholar
• Eddahibi S, Humbert M, Fadel E et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J. Clin. Invest.108(8), 1141–1150 (2001).
   PubMed Web of Science ®Google Scholar
• Eddahibi S, Chaouat A, Morrell N et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation108(15), 1839–1844 (2003).
   PubMed Web of Science ®Google Scholar
• Long L, Aldashev AA, Hensiek A et al. Preliminary identification of genetic loci associated with high altitude pulmonary hypertension by association mapping. Thorax57(Suppl. 3), S110 (2002).
   PubMedGoogle Scholar
• Olson TP, Snyder EM, Frantz RP, Turner ST, Johnson BD. Repeat length polymorphism of the serotonin transporter gene influences pulmonary artery pressure in heart failure 1. Am. Heart J.153(3), 426–432 (2007).
   PubMed Web of Science ®Google Scholar
• Meyrick B, Reid L. Pulmonary-hypertension. Anatomic and physiologic correlates. Clin. Chest Med.4(2), 199–217 (1983).
   PubMedGoogle Scholar
• Heath D, Smith P, Gosney J et al. The pathology of the early and late stages of primary pulmonary hypertension. Br. Heart J.58(3), 204–213 (1987).
   PubMedGoogle Scholar
• Simonneau G, Galie N, Rubin LJ et al. Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol.43(12), 5S–12S (2004).
   PubMed Web of Science ®Google Scholar
• Loyd JE, Butler MG, Foroud TM, Conneally PM, Phillips JA, Newman JH. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary-hypertension. Am. J. Resp. Crit. Care Med.152(1), 93–97 (1995).
   PubMed Web of Science ®Google Scholar
• Machado RD, Pauciulo MW, Thomson JR et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am. J. Hum. Gen.68(1), 92–102 (2001).
   PubMed Web of Science ®Google Scholar
• Fujiwara M, Yagi H, Matsuoka R et al. Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension. Circ. J.72(1), 127–133 (2008).
   PubMedGoogle Scholar
• Sankelo M, Flanagan JA, Machado R et al. BMPR2 mutations have short lifetime expectancy in primary pulmonary hypertension. Hum. Mutat.26(2), 119–124 (2005).
   PubMedGoogle Scholar
• Baloira A, Vilarino C, Leiro V, Valverde D. Mutations in the gene encoding bone morphogenetic protein receptor 2 in patients with idiopathic pulmonary arterial hypertension 1. Arch. Bronconeumol.44(1), 29–34 (2008).
   PubMedGoogle Scholar
• Thomson JR, Machado RD, Pauciulo MW et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family. J. Med. Gen.37(10), 741–745 (2000).
   PubMed Web of Science ®Google Scholar
• Lane KB, Machado RD, Pauciulo MW et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. Nat. Genet.26(1), 81–84 (2000).
   PubMed Web of Science ®Google Scholar
• Moudgil R, Michelakis ED, Archer SL. Hypoxic pulmonary vasoconstriction. J. Appl. Physiol.98(1), 390–403 (2005).
   PubMed Web of Science ®Google Scholar
• Silvani P, Camporesi A. Drug-induced pulmonary hypertension in newborns: a review. Curr. Vasc. Pharmacol.5(2), 129–133 (2007).
   PubMedGoogle Scholar
• MacLean MR, Herve P, Eddahibi S, Adnot S. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br. J. Pharmacol.131(2), 161–168 (2000).
   PubMed Web of Science ®Google Scholar
• Murphy DL, Lerner A, Rudnick G, Lesch KP. Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol. Interv.4(2), 109–123 (2004).
   PubMedGoogle Scholar
• Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: structure, regulation and function. Nat. Rev. Neurosci.4(1), 13–25 (2003).
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol. Ther.95(1), 73–88 (2002).
   PubMed Web of Science ®Google Scholar
• Ramamoorthy S, Bauman AL, Moore KR et al. Antidepressant-sensitive and cocaine-sensitive human serotonin transporter–molecular-cloning, expression, and chromosomal localization. Proc. Natl Acad. Sci. USA90(6), 2542–2546 (1993).
   PubMed Web of Science ®Google Scholar
• Lesch KP, Wolozin BL, Murphy DL, Riederer P. Primary structure of the human platelet serotonin uptake site–identity with the brain-serotonin transporter. J. Neurochem.60(6), 2319–2322 (1993).
   PubMed Web of Science ®Google Scholar
• Fumeron F, Betoulle D, Nicaud V et al. Serotonin transporter gene polymorphism and myocardial infarction–Etude Cas-te’moins de’ l’infarctus du myocarde (ECTIM) 1. Circulation105(25), 2943–2945 (2002).
   PubMedGoogle Scholar
• Coto E, Reguero JR, Alvarez V et al. 5-hydroxytryptamine 5-HT2A receptor and 5-hydroxytryptamine transporter polymorphisms in acute myocardial infarction. Clin. Sci.104(3), 241–245 (2003).
   Google Scholar
• Narita N, Narita M, Takashima S, Nakayama M, Nagai T, Okado N. Serotonin transporter gene variation is a risk factor for sudden infant death syndrome in the Japanese population. Pediatrics107(4), 690–692 (2001).
   PubMedGoogle Scholar
• Weese-Mayer DE, Berry-Kravis EM, Maher BS, Silvestri JM, Curran ME, Marazita ML. Sudden infant death syndrome: association with a promoter polymorphism of the serotonin transporter gene. Am. J. Med. Genet. A117(3), 268–274 (2003).
   Google Scholar
• Narita M, Nishigami N, Narita N et al. Association between serotonin transporter gene polymorphism and chronic fatigue syndrome. Biochem. Biophys. Res. Comm.311(2), 264–266 (2003).
   PubMedGoogle Scholar
• Willers ED, Newman JH, Loyd JE et al. Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension. Am. J. Resp. Crit. Care Med.173(7), 798–802 (2006).
   PubMed Web of Science ®Google Scholar
• Machado RD, Koehler R, Glissmeyer E et al. Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am. J. Resp. Crit. Care Med.173(7), 793–797 (2006).
   PubMed Web of Science ®Google Scholar
• MacLean MR, Deuchar GA, Hicks MN et al. Overexpression of the 5-hydroxytryptamine transporter gene. Effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation109(17), 2150–2155 (2004).
   PubMed Web of Science ®Google Scholar
• Guignabert C, Izikki M, Tu LI et al. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ. Res.98(10), 1323–1330 (2006).
   PubMed Web of Science ®Google Scholar
• Eddahibi S, Hanoun N, Lanfumey L et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J. Clin. Invest.105(11), 1555–1562 (2000).
   PubMed Web of Science ®Google Scholar
• Morecroft I, Loughlin L, Nilsen M et al. Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries. J. Pharmacol. Exp. Ther.313(2), 539–548 (2005).
   PubMed Web of Science ®Google Scholar
• Nagaoka T, Gebb SA, Karoor V et al. Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat. J. Appl. Physiol.100(3), 996–1002 (2006).
   PubMed Web of Science ®Google Scholar
• Marcos E, Adnot S, Pham MH et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am. J. Resp. Crit. Care Med.168(4), 487–493 (2003).
   PubMed Web of Science ®Google Scholar
• Guignabert C, Raffestin B, Benferhat R et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation111(21), 2812–2819 (2005).
   PubMed Web of Science ®Google Scholar
• Laudi S, Trump S, Schmitz V et al. Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am. J. Physiol. Lung Cell. Mol. Physiol.293(3), L630–L638 (2007).
   PubMed Web of Science ®Google Scholar
• Marcos E, Fadel E, Sanchez O et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ. Res.94(9), 1263–1270 (2004).
   PubMed Web of Science ®Google Scholar
• Lawrie A, Spiekerkoetter E, Martinez EC et al. Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ. Res.97(3), 227–235 (2005).
   PubMedGoogle Scholar
• Liu YL, Suzuki YJ, Day RM, Fanburg BL. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ. Res.95(6), 579–586 (2004).
   PubMed Web of Science ®Google Scholar
• Lee SL, Wang WW, Lanzillo JJ, Fanburg BL. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary-artery smooth-muscle cells in culture. Am. J. Physiol.266(1), L46–L52 (1994).
   Google Scholar
• Welsh DJ, Harnett M, MacLean M, Peacock AJ. Proliferation and signaling in fibroblasts. Role of 5-hydroxytryptamine(2A) receptor and transporter. Am. J. Resp. Crit. Care Med.170(3), 252–259 (2004).
   PubMed Web of Science ®Google Scholar
• Dempsie Y, Morecroft I, Welsh DJ et al. Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation117(22), 2978–2937 (2008).
   Google Scholar
• Mair K, MacLean M, Morecroft I, Dempsie Y, Palmer T. Novel interactions between the 5-HT transporter, 5-HT1B receptors and Rho kinase in vivo and in pulmonary fibroblasts. Br. J. Pharmacol.155(4), 606–616 (2008).
   PubMedGoogle Scholar
• Morecroft I, Heeley RP, Prentice HM, Kirk A, MacLean MR. 5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br. J. Pharmacol.128(3), 730–734 (1999).
   PubMed Web of Science ®Google Scholar
• Keegan A, Morecroft I, Smillie D, Hicks MN, MacLean MR. Contribution of the 5-HT1B receptor to hypoxia-induced pulmonary hypertension. Converging evidence using 5-HT1B-receptor knockout mice and the 5-HT1B/1D-receptor antagonist GR127935. Circ. Res.89(12), 1231–1239 (2001).
   PubMed Web of Science ®Google Scholar
• MacLean MR, Clayton RA, Templeton AGB, Morecroft I. Evidence for 5-HT1-like receptor-mediated vasoconstriction in human pulmonary artery. Br. J. Pharmacol.119(2), 277–282 (1996).
   PubMed Web of Science ®Google Scholar
• Launay JM, Herve P, Peoc’h K et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat. Med.8(10), 1129–1135 (2002).
   PubMed Web of Science ®Google Scholar
• Walther DJ, Peter JU, Winter S et al. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet α-granule release. Cell115(7), 851–862 (2003).
   PubMed Web of Science ®Google Scholar
• Guilluy C, Rolli-Derkinderen M, Tharaux PL, Melino G, Pacaud P, Loirand G. Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells. J. Biol. Chem.282(5), 2918–2928 (2007).
   PubMedGoogle Scholar
• Liu JQ, Folz RJ. Extracellular superoxide enhances 5-HT-induced murine pulmonary artery vasoconstriction. Am. J. Physiol. Lung Cell. Mol. Physiol.287(1), L111–L118 (2004).
   PubMed Web of Science ®Google Scholar
• Lee SL, Wang WW, Fanburg BL. Superoxide as an intermediate signal for serotonin-induced mitogenesis. Free Radic. Biol. Med.24(5), 855–858 (1998).
   PubMed Web of Science ®Google Scholar
• Lee SL, Wang WW, Finlay GA, Fanburg BL. Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion. Am. J. Physiol. Lung Cell. Mol. Physiol.277(2), L282–L291 (1999).
   PubMed Web of Science ®Google Scholar
• Greenway S, van Suylen RJ, Sarvaas GD et al. S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am. J. Pathol.164(1), 253–262 (2004).
   PubMedGoogle Scholar
• Das M, Bouchey DM, Moore MJ, Hopkins DC, Nemenoff RA, Stenmark KR. Hypoxia-induced proliferative response of vascular adventitial fibroblasts is dependent on G protein-mediated activation of mitogen-activated protein kinases. J. Biol. Chem.276(19), 15631–15640 (2001).
   PubMed Web of Science ®Google Scholar
• Mortimer HJ, Peacock AJ, Kirk A, Welsh DJ. p38 MAP kinase: essential role in hypoxia-mediated human pulmonary artery fibroblast proliferation. Pulm. Pharmacol. Ther.20(6), 718–725 (2007).
   PubMedGoogle Scholar
• Samuvel DJ, Jayanthi LD, Bhat NR, Ramamoorthy S. A role for p38 mitogen-activated protein kinase in the regulation of the serotonin transporter: evidence for distinct cellular mechanisms involved in transporter surface expression. J. Neurosci.25(1), 29–41 (2005).
   PubMed Web of Science ®Google Scholar
• Zhu CB, Carneiro AM, Dostmann WR, Hewlett WA, Blakely RD. p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process. J. Biol. Chem.280(16), 15649–15658 (2005).
   PubMed Web of Science ®Google Scholar
• Kimura K, Ito M, Amano M et al. Regulation of myosin phosphatase by Rho and Rho-Associated kinase (Rho-kinase). Science273(5272), 245–248 (1996).
   PubMed Web of Science ®Google Scholar
• Fagan KA, Oka M, Bauer NR et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am. J. Physiol. Lung Cell. Mol. Physiol.287(4), L656–L664 (2004).
   PubMed Web of Science ®Google Scholar
• Robertson TP, Dipp M, Ward JP, Aaronson PI, Evans AM. Inhibition of sustained hypoxic vasoconstriction by Y-27632 in isolated intrapulmonary arteries and perfused lung of the rat. Br. J. Pharmacol.131(1), 5–9 (2000).
   PubMed Web of Science ®Google Scholar
• Weigand L, Sylvester JT, Shimoda LA. Mechanisms of endothelin-1-induced contraction in pulmonary arteries from chronically hypoxic rats. Am. J. Physiol. Lung Cell. Mol. Physiol.290(2), L284–L290 (2006).
   Google Scholar
• Janssen LJ, Premji M, Netherton S, Coruzzi J, Lu-Chao H, Cox PG. Vasoconstrictor actions of isoprostanes via tyrosine kinase and Rho kinase in human and canine pulmonary vascular smooth muscles. Br. J. Pharmacol.132(1), 127–134 (2001).
   PubMed Web of Science ®Google Scholar
• Han W, Tang X, Wu H, Liu Y, Zhu D. Role of ERK1/2 signaling pathways in 4-aminopyridine-induced rat pulmonary vasoconstriction. Eur. J. Pharmacol.569(1–2), 138–144 (2007).
   PubMedGoogle Scholar
• Mitani Y, Mutlu A, Russell JC, Brindley DN, DeAlmeida J, Rabinovitch M. Dexfenfluramine protects against pulmonary hypertension in rats. J. Appl. Physiol.93(5), 1770–1778 (2002).
   PubMed Web of Science ®Google Scholar
• Rochefort GY, Lemaire MC, Eder V et al. Dexfenfluramine does not worsen but moderates progression of chronic hypoxia-induced pulmonary hypertension. Eur. J. Pharmacol.550(1–3), 149–154 (2006).
   PubMedGoogle Scholar
• Weir EK, Reeve HL, Huang JMC et al. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation94(9), 2216–2220 (1996).
   PubMed Web of Science ®Google Scholar
• Reeve HL, Archer SL, Soper M, Weir EK. Dexfenfluramine increases pulmonary smooth muscle intracellular Ca2+ independent of membrane potential. Am. J. Physiol. Lung Cell. Mol. Physiol.277(3), L662–L666 (1999).
   Google Scholar
• Higenbottam T, Marriott H, Cremona G, Laude E, Bee D. The acute effects of dexfenfluramine on human and porcine pulmonary vascular tone and resistance. Chest116(4), 921–930 (1999).
   PubMed Web of Science ®Google Scholar
• Patnaude LA, Undem BJ, O’Rourke ST. Dexfenfluramine-induced contraction of human and rat isolated pulmonary arteries. Eur. J. Pharmacol.401(2), 229–234 (2000).
   PubMedGoogle Scholar
• Lee SL, Wang WW, Fanburg BL. Dexfenfluramine as a mitogen signal via the formation of superoxide anion. FASEB J.15(7), 1324–1325 (2001).
   PubMedGoogle Scholar
• Hironaka E, Hongo M, Sakai A et al. Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc. Res.60(3), 692–699 (2003).
   PubMed Web of Science ®Google Scholar
• Morecroft I, Dempsie Y, Bader M et al. Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension49(1), 232–236 (2007).
   PubMed Web of Science ®Google Scholar
• Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest130(6), 1657–1663 (2006).
   PubMed Web of Science ®Google Scholar
• Lu J, Shimpo H, Shimamoto A et al. Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats. J. Thorac. Cardiovasc.Surg.128(6), 850–859 (2004).
   PubMedGoogle Scholar
• Massague J, Seoane J, Wotton D. Smad transcription factors 2. Genes Dev.19(23), 2783–2810 (2005).
   PubMed Web of Science ®Google Scholar
• Yang XD, Long L, Southwood M et al. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ. Res.96(10), 1053–1063 (2005).
   PubMed Web of Science ®Google Scholar
• Long L, MacLean MR, Jeffery TK et al. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ. Res.98(6), 818–827 (2006).
   PubMed Web of Science ®Google Scholar
• Kretzschmar M, Doody J, Massague J. Opposing BMP and EGF signalling pathways converge on the TGF-β family mediator Smad1. Nature389(6651), 618–622 (1997).
   PubMed Web of Science ®Google Scholar
• Humbert M, Deng Z, Simonneau G et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur. Resp. J.20(3), 518–523 (2002).
   PubMed Web of Science ®Google Scholar
• Linder AE, Diaz J, Ni W, Szasz T, Burnett R, Watts SW. Vascular reactivity, 5-HT uptake, and blood pressure in the serotonin transporter knockout rat. Am. J. Physiol. Heart Circ. Physiol.294(4), H1745–H1752 (2008).
   Google Scholar
• Villalon CM, Centurion D. Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch. Pharmacol.376(1–2), 45–63 (2007).
   PubMed Web of Science ®Google Scholar
• Sharma SK, Zahradka P, Chapman D, Kumamoto H, Takeda N, Dhalla NS. Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate. J. Pharmacol. Exp. Ther.290(3), 1475–1481 (1999).
   PubMed Web of Science ®Google Scholar
• Kawut SM, Horn EM, Berekashvili KK et al. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm. Pharmacol. Ther.19(5), 370–374 (2006).
   PubMed Web of Science ®Google Scholar
• Chambers CD, Hernandez-Diaz S, Van Marter LJ et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med.354(6), 579–587 (2006).
   PubMed Web of Science ®Google Scholar
• Fornaro E, Li D, Pan J, Belik J. Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am. J. Respir. Crit. Care Med.176(10), 1035–1040 (2007).
   PubMedGoogle Scholar